Fact check
“Acting Attorney General Todd Blanche issued a final rule in April 2024 that followed the HHS recommendation but limited Schedule III status to marijuana products currently sold by state-licensed medical dispensaries or approved in the future by the FDA.”
Reasoning
The provided evidence quotes the rule's issuance date (April 2024), the acting AG's name (Todd Blanche), and the specific limitation on Schedule III eligibility to current medical dispensary products or those approved by the FDA, matching the claim exactly.
On confidence: The claim is directly supported by a primary source excerpt that states Acting Attorney General Todd Blanche issued the final rule in April 2024 and limited Schedule III status to marijuana products sold by state-licensed medical dispensaries or future FDA‑approved products.
Important context
The rule follows a HHS recommendation to place marijuana in Schedule III but adds a restriction on which products qualify, reflecting a policy nuance rather than a full reclassification.
Evidence
Supporting (1)
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
"potential for abuse," recommended placing it in Schedule III, which includes prescription drugs such as ketamine, anabolic steroids, and Tylenol with codeine. Last April, Acting Attorney General Todd Blanche issued a final rule that…
Contextual (1)
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
abuse." But as a recent report from the Government Accountability Office (GAO) notes, the statute does not clearly define either criterion, opening the door to debatable and changeable regulatory judgments with far-reaching criminal…
Limitations
The evidence comes from a single media article; no additional government documents or official statements are provided to corroborate the details. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.
- Last verified:
- Oct 1, 2026, 4:49 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Hazy Drug Classification Criteria Invite Dubious Bureaucratic JudgmentsReason · Jacob Sullum